Telehealth company Hims & Hers Health (NYSE:HIMS) announced in Q4 CY2024, with sales up 95.1% year on year to $481.1 million.
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Revenue excluding its GLP-1 offering increased 43% to $1.2 billion in 2024 from a year earlier, said Chief Financial Officer Yemi Okupe. Including sales of its weight-loss treatments, revenue surged ...
Hims & Hers Health, Inc. (NYSE:HIMS) announced the acquisition of a California-based peptide facility to enhance its domestic ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Hims & Hers Health beat fourth-quarter estimates and guided for better-than-expected revenue in the first quarter and 2025. The telehealth provider logged earnings of 11 cents a share on revenue of ...
Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $36.43, ...
Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...
Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...